Drug Profile
ACH 5548
Alternative Names: ACH-0145548; ACH-5548Latest Information Update: 28 Jul 2021
Price :
$50
*
At a glance
- Originator Achillion Pharmaceuticals
- Class Small molecules
- Mechanism of Action Complement factor D inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Autoimmune disorders
Most Recent Events
- 28 Jul 2021 No recent reports of development identified for phase-I development in Autoimmune-disorders(In volunteers) in New Zealand (PO)
- 28 Jan 2020 Achillion Pharmaceuticals has been acquired by Alexion Pharmaceuticals
- 14 May 2019 Achillion Pharmaceuticals has patent protection for ACH 5548 in USA